Journal September 25, 2026 4 min read

How is neuroinflammation measured?

Neuroinflammation is assessed through a combination of molecular, cellular, and imaging biomarkers, with many mechanistic insights derived from animal models and in vitro systems.

peptides-pro Editorial

Neuroinflammation is measured using a combination of molecular, cellular, and imaging biomarkers that reflect the activation of glial cells and the release of inflammatory mediators. In research settings, common approaches include quantifying pro-inflammatory cytokines (e.g., IL-1β, TNF-α, IL-6) in cerebrospinal fluid or brain tissue, assessing microglial and astrocytic activation markers (e.g., Iba-1, GFAP), and detecting inflammasome components such as NLRP3. Advanced imaging techniques, such as positron emission tomography (PET) with ligands targeting the 18 kDa translocator protein (TSPO), are also employed in clinical and preclinical studies to visualize neuroinflammatory changes.

The work centres on the NLRP3 inflammasome pathway and its modulation by AMPK signalling, as well as other inflammatory cascades involving NF-κB and MAPK.

Research Studies

Magnesium sulphate and NMDA receptor blockade in neonatal asphyxia

In a randomized controlled trial, intravenous magnesium sulphate administered within 6 hours of birth at a dose of 250 mg/kg was evaluated for its potential to reduce hospital stay and improve short-term outcomes in term neonates with birth asphyxia. The proposed mechanism involves blockade of NMDA receptors, which limits cellular calcium influx and subsequent neuroinflammation [1].

Tauroursodeoxycholate and liver-targeted therapy for diabetic macular edema

Diabetic macular edema is associated with systemic inflammation and hepatic metabolic dysfunction. A clinical trial is investigating whether nutraceutical supplements such as tauroursodeoxycholate, a bile acid, can address neuroinflammation and vascular dysfunction in diabetic retinopathy by targeting liver metabolism [2].

AMPK activation and NLRP3 inflammasome suppression in traumatic brain injury

In a weight-drop model of traumatic brain injury in Sprague-Dawley rats, AMPK activators including metformin, quercetin, resveratrol, cinnamaldehyde, and berberine were studied for their effects on NLRP3 inflammasome-mediated neuroinflammation. The study investigated whether these compounds could suppress inflammasome activation and provide neuroprotection [3].

Natural medicines and mechanistic insights in Alzheimer's disease

A bibliometric analysis and narrative review mapped research trends in natural medicines for Alzheimer's disease from 2001 to 2025. The review highlighted representative mechanistic evidence, including modulation of neuroinflammatory pathways, from experimental studies [4].

Oxiracetam and cognitive dysfunction in neurological disorders

A narrative review evaluated the mechanistic basis, clinical efficacy, and safety of oxiracetam for cognitive impairment across various neurological disorders. The review synthesized preclinical and clinical literature, including effects on cholinergic and glutamatergic systems that may influence neuroinflammation [6].

NMNAT-1 and NAD+ homeostasis in neuroprotection

Nicotinamide mononucleotide adenylyltransferase 1 (NMNAT-1) catalyzes the final step in NAD+ biosynthesis. Direct human genetic evidence establishes NMNAT-1 as a causal gene in inherited axonal degeneration, and age-associated NAD+ decline has been implicated in brain aging and neurodegenerative disorders, with links to inflammation and neuronal maintenance [7].

Coenzyme Q10 and sevoflurane-induced neuroinflammation in mouse hippocampal neurons

A study in mouse hippocampal neurons investigated whether coenzyme Q10 alleviates sevoflurane-induced neuroinflammation by regulating apolipoprotein E and phosphorylated tau protein levels. A corrigendum noted a methodological error in the detection of tau phosphorylation [8].

Bilirubin and microglial lipophagy via AMPK-mTOR signaling

Unconjugated bilirubin-induced neuroinflammation plays a role in bilirubin encephalopathy. Research delineated the role and molecular mechanisms of lipophagy in microglia via the AMPK-mTOR signaling pathway, providing insights into how bilirubin impacts neuroinflammation [10].

Pterostilbene and hyperhomocysteinemia-induced cognitive impairment

Pterostilbene, a natural stilbene derivative, was studied for its neuroprotective mechanisms in hyperhomocysteinemia-induced cognitive impairment using in silico, proteomics, and experimental validation approaches. The research explored its antioxidant and anti-inflammatory properties [11].

TRIM28 SUMOylation of IRF3 in astrocytes and ischemic cerebral injury

In ischemic cerebral injury, the E3 SUMOylase TRIM28 was found to SUMOylate IRF3 in astrocytes, driving neutrophil infiltration and contributing to neuroinflammation. This study illuminated a molecular mechanism underlying neuro-immune crosstalk [12].

Astrocytic failure in Parkinson's disease

A system-level model of Parkinson's disease pathogenesis proposed that astrocyte dysfunction, or astrocytopathy, is a central driver of the disease, extending beyond a purely neurodegenerative framework to involve multicellular failure of the neuroglial unit [9].

Nutritional paradox in uremia and protein-energy wasting

In advanced chronic kidney disease, protein-energy wasting is associated with systemic anabolic resistance. A proposed 'sensitize-then-feed' framework addresses the molecular hierarchy driving this barrier, which may involve inflammatory pathways [5].

If you are reading this for personal health reasons

The materials and compounds discussed here are sold for laboratory research use only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.